Germany’s IQWiG Fells AstraZeneca’s Caprelsa Again, Proving Mortality Trumps All

AstraZeneca’s Caprelsa has failed to take advantage of a second assessment chance at IQWiG, and it seems clear the company and the assessor never saw eye-to-eye on trial design.